Ketamine Metabolites for the Treatment of Depression and Pain
Posted Feb 07 2012 7:00pm
Description of Invention: The market continues to have a need for therapeutics for treating pain and depression that have efficacy in a high percentage of patients but have reduced anaesthetic properties and reduced abuse liability. Ketamine, a drug currently used in human anesthesia and veterinary medicine, has been shown in clinical studies to be effective in the treatment of several conditions, including the of treatment-resistant bipolar depression, major depressive disorder, neuropathic pain, and chronic pain, including complex regional pain syndrome (CRPS). However the routine use of the drug is hindered by unwanted central nervous system (CNS) effects and a patient response rate of ~70%. New data suggests that ketamine metabolites can be used with similar results but with an increase in patient response rates and a decrease in undesirable side effects.
Applications: Treatment of pain and depression.
Advantages:
Increased number of patients able to respond to the treatment because it bypasses the human metabolic machinery needed to convert the drug into its active metabolite(s).
Decreased CNS side effects.
Development Status: In vivo data available (animal)
Zarate CA Jr., et al. Relationship of Ketamine’s Plasma Metabolites with Response and Diagnosis, and Side Effects in Major Depression. Manuscript in preparation.
Ibrahim L, et al. Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs. Add-on Riluzole: Results from a Four-Week, Double-Blind, Placebo-Controlled Study. Neuropsychopharmacology, in press.
Zhao X, et al. Population Pharmacokinetic Modeling of Ketamine and Three Major Metabolites in Patients with Treatment-Resistant Bipolar Depression. Br. J. Clin. Phamaco., in press.
Collaborative Research Opportunity: The National Institute on Aging, Laboratory of Clinical Investigation, Bioanalytical Chemistry and Drug Discovery Section, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Nicole Guyton, Ph.D. at darackn@mail.nih.gov . Click here to view the NIA collaborative opportunity announcement.
For Licensing Information Please Contact: Jaime Greene M.S. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: greenejaime@mail.nih.gov Phone: 301-435-5559 Fax: 301-402-0220
Description of Invention:
The market continues to have a need for therapeutics for treating pain and depression that have efficacy in a high percentage of patients but have reduced anaesthetic properties and reduced abuse liability. Ketamine, a drug currently used in human anesthesia and veterinary medicine, has been shown in clinical studies to be effective in the treatment of several conditions, including the of treatment-resistant bipolar depression, major depressive disorder, neuropathic pain, and chronic pain, including complex regional pain syndrome (CRPS). However the routine use of the drug is hindered by unwanted central nervous system (CNS) effects and a patient response rate of ~70%. New data suggests that ketamine metabolites can be used with similar results but with an increase in patient response rates and a decrease in undesirable side effects.
Applications:
Treatment of pain and depression.
Advantages:
Development Status:
In vivo data available (animal)
Inventors:
Carlos A Zarate (NIMH)
Irving W Wainer (NIA)
Ruin Moaddel (NIA)
Patent Status:
HHS, Reference No. E-092-2011/0
US, Application No. 61/547,336 filed 14 Oct 2011
Related Technologies:
US, Application No. 11/688,603 filed 20 Mar 2007, Reference No. E-174-2006/0
US, Application No. 60/785,108 filed 22 Mar 2006, Reference No. E-174-2006/0
and related international applications
Relevant Publication:
Collaborative Research Opportunity:
The National Institute on Aging, Laboratory of Clinical Investigation, Bioanalytical Chemistry and Drug Discovery Section, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Nicole Guyton, Ph.D. at darackn@mail.nih.gov . Click here to view the NIA collaborative opportunity announcement.
For Licensing Information Please Contact:
Jaime Greene M.S.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: greenejaime@mail.nih.gov
Phone: 301-435-5559
Fax: 301-402-0220
Ref No: 2362
Updated: 02/2012